Sedation & immunomodulation

Anesthesiology Clinics

Volumn 29, Issue 4, 2011, Pages 687-706

  Sanders, Robert D ^a,b   Hussell, Tracy ^b   Maze, Mervyn ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Benzodiazepine; Dexmedetomidine; Infection; Morphine; Propofol; Sepsis

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; DEXMEDETOMIDINE; DIAZEPAM; FENTANYL DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR; OPIATE DERIVATIVE; PROPOFOL; SEDATIVE AGENT;

CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; INFECTION SENSITIVITY; INNATE IMMUNITY; MORTALITY; REVIEW; SEDATION; SEPSIS; SIDE EFFECT;

EID: 81055150441     PISSN: 19322275     EISSN: 22103538     Source Type: Journal    
DOI: 10.1016/j.anclin.2011.09.008     Document Type: Review

References (123)

1. Harrison D.A., Welch C.A., Eddleston J.M. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006, 10(2):R42.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6(11):813-822.
4. Matute-Bello G., Frevert C.W., Martin T.R. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008, 295(3):L379-L399.
5. Wan L., Bagshaw S.M., Langenberg C., et al. Pathophysiology of septic acute kidney injury: what do we really know?. Crit Care Med 2008, 36(4 Suppl):S198-S203.
6. MacDonald A., Adamis D., Treloar A., et al. C-reactive protein levels predict the incidence of delirium and recovery from it. Age Ageing 2007, 36:222-225.
7. Annane D., Bellisant E., Cavaillon J.M. Septic shock. Lancet 2005, 365:63-78.
8. Pandharipande P.P., Sanders R.D., Girard T., et al. Comparison of sedation with dexmedetomidine versus lorazepam in septic ICU patients. Critical Care 2008, 12:P275.
9. Pandharipande P.P., Pun B.T., Herr D.L., et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients. The MENDS randomized controlled trial. JAMA 2007, 298:2644-2653.
10. Nelson L.E., Lu J., Guo T., et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003, 98:428-436.
11. Sanders R.D., Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs 2007, 8:25-33.
12. Smith I.M., Kennedy L.R., Regné-Karlsson M.H., et al. Adrenergic mechanisms in infection. III. Alpha- and beta-receptor blocking agents in treatment. Am J Clin Nutr 1977, 30(8):1285-1288.
13. Nance D.M., Sanders V.M. Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun 2007, 21(6):736-745.
14. Heine J., Leuwer M., Scheinichen D., et al. Flow cytometry evaluation of the in vitro influence of four i.v. anaesthetics on respiratory burst of neutrophils. Br J Anaesth 1996, 77:387-392.
15. Kelbel I., Weiss M. Anaesthetics and immune function. Curr Opin Anaesthesiol 2001, 14(6):685-691.
16. Mikawa K., Akamatsu H., Nishina K., et al. Propofol inhibits human neutrophil functions. Anesth Analg 1998, 87:695-700.
17. Corcoran T.B., Engel A., Sakamoto H., et al. The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function. Br J Anaesth 2006, 97(6):825-831.
18. Heller A., Heller S., Blecken S., et al. Effects of intravenous anesthetics on bacterial elimination in human blood in vitro. Acta Anaesthesiol Scand 1998, 42:518-526.
19. Krumholz W., Endrass J., Hempelmann G. Propofol inhibits phagocytosis and killing of Staphylococcus aureus and Escherichia coli by polymorphonuclear leukocytes in vitro. Can J Anaesth 1994, 41:446-449.
20. Chen R.M., Wu C.H., Chang H.C., et al. Propofol suppresses macrophage functions and modulates mitochondrial membrane potential and cellular adenosine triphosphate synthesis. Anesthesiology 2003, 98:1178-1185.
21. Chang H., Tsai S.Y., Chang Y., et al. Therapeutic concentration of propofol protects mouse macrophages from nitric oxide-induced cell death and apoptosis. Can J Anaesth 2002, 49:477-480.
22. Chen R.M., Wu G.J., Tai Y.T., et al. Propofol reduces nitric oxide biosynthesis in lipopolysaccharide-activated macrophages by downregulating the expression of inducible nitric oxide synthase. Arch Toxicol 2003, 77:418-423.
23. Chen R.M., Chen T.G., Chen T.L., et al. Anti-inflammatory and antioxidative effects of propofol on lipopolysaccharide-activated macrophages. Ann N Y Acad Sci 2005, 1042:262-271.
24. Kotani N., Hashimoto H., Sessler D.I., et al. Expression of genes for proinflammatory cytokines in alveolar macrophages during propofol and isoflurane anesthesia. Anesth Analg 1999, 89(5):1250-1256.
25. Ploppa A., Kiefer R.T., Nohe B., et al. Dose-dependent influence of barbiturates but not of propofol on human leukocyte phagocytosis of viable Staphylococcus aureus. Crit Care Med 2006, 34(2):478-483.
26. Huettemann E., Jung A., Vogelsang H., et al. Effects of propofol vs. methohexital on neutrophil function and immune status in critically ill patients. J Anesth 2006, 20(2):86-91.
27. Heine J., Jaeger K., Osthaus A., et al. Anaesthesia with propofol decreases FMLP-induced neutrophil respiratory burst but not phagocytosis compared with isoflurane. Br J Anaesth 2000, 85:424-430.
28. Inada T., Taniuchi S., Shingu K., et al. Propofol depressed neutrophil hydrogen peroxide production more than midazolam, whereas adhesion molecule expression was minimally affected by both anesthetics in rats with abdominal sepsis. Anesth Analg 2001, 92(2):437-441.
29. Galley H.F., Dubbels A.M., Webster N.R. The effect of midazolam and propofol on interleukin-8 from human polymorphonuclear leukocytes. Anesth Analg 1998, 86(6):1289-1293.
30. O'Donnell N.G., McSharry C.P., Wilkinson P.C., et al. Comparison of the inhibitory effects of propofol, thiopentone and midazolam on neutrophil polarization in vitro in the presence or absence of human serum albumin. Br J Anaesth 1992, 69:70-74.
31. Nagata T., Kansha M., Irita K., et al. Propofol inhibits FMLP-stimulated phosphorylation of p42 mitogen-activated protein kinase and chemotaxis in human neutrophils. Br J Anaesth 2001, 86:853-858.
32. Inada T., Yamanouchi Y., Jomura S., et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia 2004, 59:954-959.
33. Pirttikangas C.O., Salo M., Mansikka M., et al. The influence of anaesthetic technique upon the immune response to hysterectomy. A comparison of propofol infusion and isoflurane. Anaesthesia 1995, 50:1056-1061.
34. Devlin E.G., Clarke R.S., Mirakhur R.K., et al. Effect of four i.v. induction agents on T-lymphocyte proliferations to PHA in vitro. Br J Anaesth 1994, 73(3):315-317.
35. Mozrzymas J.W., Teisseyre A., Vittur F. Propofol blocks voltage-gated potassium channels in human T lymphocytes. Biochem Pharmacol 1996, 52(6):843-849.
36. Song H.K., Jeong D.C. The effect of propofol on cytotoxicity and apoptosis of lipopolysaccharide-treated mononuclear cells and lymphocytes. Anesth Analg 2004, 98:1724-1728.
37. Taniguchi T., Yamamoto K., Ohmoto N., et al. Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med 2000, 28(4):1101-1106.
38. Taniguchi T., Kanakura H., Yamamoto K. Effects of posttreatment with propofol on mortality and cytokine responses to endotoxin-induced shock in rats. Crit Care Med 2002, 30(4):904-907.
39. Takemoto Y. Dose effects of propofol on hemodynamic and cytokine responses to endotoxemia in rats. J Anesth 2005, 19(1):40-44.
40. Hsu B.G., Yang F.L., Lee R.P., et al. Effects of post-treatment with low-dose propofol on inflammatory responses to lipopolysaccharide-induced shock in conscious rats. Clin Exp Pharmacol Physiol 2005, 32(1-2):24-29.
41. Kelbel I., Koch T., Weber A., et al. Alterations of bacterial clearance induced by propofol. Acta Anaesthesiol Scand 1999, 43(1):71-76.
42. Helmy S.A., Al-Attiyah R.J. The immunomodulatory effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients. Anaesthesia 2001, 56(1):4-8.
43. Kim S.N., Son S.C., Lee S.M., et al. Midazolam inhibits proinflammatory mediators in the lipopolysaccharide-activated macrophage. Anesthesiology 2006, 105(1):105-110.
44. Massoco C., Palermo-Neto J. Effects of midazolam on equine innate immune response: a flow cytometric study. Vet Immunol Immunopathol 2003, 95(1-2):11-19.
45. Matsumoto T., Ogata M., Koga K., et al. Effect of peripheral benzodiazepine receptor ligands on lipopolysaccharide-induced tumor necrosis factor activity in thioglycolate-treated mice. Antimicrob Agents Chemother 1994, 38(4):812-816.
46. Galdiero F., Bentivoglio C., Nuzzo I., et al. Effects of benzodiazepines on immunodeficiency and resistance in mice. Life Sci 1995, 57(26):2413-2423.
47. da Silva F.R., Lazzarini R., de Sá-Rocha L.C., et al. Effects of acute and long-term diazepam administrations on neutrophil activity: a flow cytometric study. Eur J Pharmacol 2003, 478(2-3):97-104.
48. Mühling J., Sablotzki A., Fuchs M., et al. Effects of diazepam on neutrophil (PMN) free amino acid profiles and immune functions in vitro. Metabolical and immunological consequences of L-alanyl-L-glutamine supplementation. J Nutr Biochem 2001, 12(1):46-54.
49. Weiss M., Mirow N., Birkhahn A., et al. Benzodiazepines and their solvents influence neutrophil granulocyte function. Br J Anaesth 1993, 70(3):317-321.
50. Finnerty M., Marczynski T.J., Amirault H.J., et al. Benzodiazepines inhibit neutrophil chemotaxis and superoxide production in a stimulus dependent manner; PK-11195 antagonizes these effects. Immunopharmacology 1991, 22(3):185-193.
51. Laschi A., Descotes J., Tachon P., et al. Adverse influence of diazepam upon resistance to Klebsiella pneumoniae infection in mice. Toxicol Lett 1983, 16(3-4):281-284.
52. Chao C.C., Sharp B.M., Pomeroy C., et al. Lethality of morphine in mice infected with Toxoplasma gondii. J Pharmacol Exp Ther 1990, 252:605-609.
53. MacFarlane A.S., Peng X., Meissler J.J., et al. Morphine increases susceptibility to oral Salmonella typhimurium infection. J Infect Dis 2000, 181:1350-1358.
54. Asakura H., Watarai M., Shirahata T., et al. Viable but nonculturable Salmonella species recovery and systemic infection in morphine-treated mice. J Infect Dis 2002, 186:1526-1529.
55. Feng P., Truant A.L., Meissler J.J., et al. Morphine withdrawal lowers host defense to enteric bacteria: spontaneous sepsis and increased sensitivity to oral Salmonella enterica serovar Typhimurium infection. Infect Immun 2006, 74:5221-5226.
56. Wang J., Barke R.A., Charboneau R., et al. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005, 174:426-434.
57. Wang J., Barke R.A., Charboneau R., et al. Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling. J Immunol 2008, 180(5):3594-3600.
58. Asakura H., Kawamoto K., Igimi S., et al. Enhancement of mice susceptibility to infection with Listeria monocytogenes by the treatment of morphine. Microbiol Immunol 2006, 50:543-547.
59. Hilburger M.E., Adler M.W., Truant A.L., et al. Morphine induces sepsis in mice. J Infect Dis 1997, 176:183-188.
60. Roy S., Cain K.J., Charboneau R.G., et al. Morphine accelerates the progression of sepsis in an experimental sepsis model. Adv Exp Med Biol 1998, 437:21-31.
61. Taniguchi T., Kidani Y., Kanakura H., et al. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2004, 32:1322-1326.
62. Taniguchi T., Kurita A., Kobayashi K., et al. Dose- and time-related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats. J Anesth 2008, 22(3):221-228.
63. Ugaz E.M., Pinheiro S.R., Guerra J.L., et al. Effects of prenatal diazepam treatment on Mycobacterium bovis-induced infection in hamsters. Immunopharmacology 1999, 41(3):209-217.
64. Hak E., Bont J., Hoes A.W., et al. Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract 2005, 22(4):375-380.
65. Decaudin D. Peripheral benzodiazepine receptor and its clinical targeting. Anticancer Drugs 2004, 15(8):737-745.
66. Cantacuzene J. Nouvelles recherches sur le monde de destruction des vibrions dans l'organisme. Ann Inst Pasteur 1898, 12:273-300.
67. Vallejo R., de Leon-Casasola O., Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004, 11(5):354-365.
68. Roy S., Wang J., Kelschenbach J., et al. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 2006, 1(1):77-89.
69. Tian M., Broxmeyer H.E., Fan Y., et al. Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J Exp Med 1997, 185(8):1517-1522.
70. Weinert C.R., Kethireddy S., Roy S. Opioids and infections in the intensive care unit should clinicians and patients be concerned?. J Neuroimmune Pharmacol 2008, 3(4):218-229.
71. Szabo I., Rojavin M., Bussiere J.L., et al. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 1995, 267:703-706.
72. Tubaro E., Santiangeli C., Belogi L., et al. Methadone vs morphine: comparison of their effect on phagocytic functions. Int J Immunopharmacol 1987, 9(1):79-88.
73. Tomei E.Z., Renaud F.L. Effect of morphine on Fc-mediated phagocytosis by murine macrophages in vitro. J Neuroimmunol 1997, 74(1-2):111-116.
74. Tomassini N., Renaud F., Roy S., et al. Morphine inhibits Fc-mediated phagocytosis through μ and δ opioid receptors. J Neuroimmunol 2004, 147(1-2):131-133.
75. Choi Y., Chuang L.F., Lam K.M., et al. Inhibition of chemokine-induced chemotaxis of monkey leukocytes by mu-opioid receptor agonist. In Vivo 1999, 13:389-396.
76. Miyagi T., Chuang L.F., Lam K.M., et al. Opioid suppress chemokine-mediated migration of monkey neutrophils and monocytes - an instant response. Immunopharmacology 2001, 47:53-62.
77. Fecho K., Maslonek K.A., Coussons-Read M.E., et al. Macrophage-derived nitric oxide is involved in the depressed con A-responsiveness of splenic lymphocytes from rats administered morphine in vivo. J Immunol 1994, 152:5845-5852.
78. Pacifici R., Minetti M., Zuccaro P., et al. Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide release. Int J Immunopharmacol 1995, 17(9):771-777.
79. Stefano G.B., Cadet P., Fimiani C., et al. Morphine stimulates iNOS expression via a rebound from inhibition in human macrophages: nitric oxide involvement. Int J Immunopathol Pharmacol 2001, 14(3):129-138.
80. Wang J., Charboneau R., Balasubramanian S., et al. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 2002, 71(5):782-790.
81. Sharp B.M., Keane W.F., Suh H.J., et al. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology 1985, 117(2):793-795.
82. Bhat R.S., Bhaskaran M., Mongia A., et al. Morphine-induced macrophage apoptosis: oxidative stress and strategies for modulation. J Leukoc Biol 2004, 75(6):1131-1138.
83. Roy S., Barke R.A., Loh H.H. Mu-receptor knockout mice: the role of mu-opioid receptor in immune functions. Brain Res Mol Brain Res 1998, 61(1-2):190-194.
84. Roy S., Charboneau R., Barke R.A., et al. Role of mu-opioid receptor in immune function. Adv Exp Med Biol 2001, 493:117-126.
85. Singhal P.C., Bhaskaran M., Patel J., et al. Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J Immunol 2002, 168(8):4025-4033.
86. Lysle D.T., Hoffman K.E., Dykstra L.A. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J Pharmacol Exp Ther 1996, 277:1533-1540.
87. Roy S., Wang J.H., Balasubramanian S., et al. Role of hypothalamic-pituitary axis in morphine-induced alteration in thymic cell distribution using mu-opioid receptor knockout mice. J Neuroimmunol 2001, 116(2):147-155.
88. Carr D.J., France C.P. Immune alterations in chronic morphine treated rhesus monkeys. Adv Exp Med Biol 1993, 335:35-39.
89. Wang J., Charboneau R., Balasubramanian S., et al. Morphine modulates lymph node-derived T lymphocyte function: role of caspase-3, -8, and nitric oxide. J Leukoc Biol 2001, 70(4):527-536.
90. Flores L.R., Hernandez M.C., Bayer B.M. Acute immunosuppressive effects of morphine: lack of involvement of pituitary and adrenal factors. J Pharmacol Exp Ther 1994, 268:1129-1134.
91. Roy S., Wang J.H., Sumandeep G., et al. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T bet. J Neuroimmunol 2004, 147:78-81.
92. Roy S., Wang J.H., Charboneau R.G., et al. Morphine induces CD4+ T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway. J Immunol 2005, 175(10):6361-6367.
93. Avidor-Reiss T., Nevo I., Levy R., et al. Chronic opioid treatment induces adenylyl cyclase V superactivation: involvement of Gbg. J Biol Chem 1996, 271(35):21309-21315.
94. Singhal P.C., Kapasi A.A., Franki N., et al. Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology 2000, 100(1):57-62.
95. Yin D., Mufson R.A., Wang R., et al. Fas-mediated cell death promoted by opioids. Nature 1999, 397(6716):218.
96. Singhal P., Kapasi A., Reddy K., et al. Opiates promote T cell apoptosis through JNK and caspase pathway. Adv Exp Med Biol 2001, 493:127-135.
97. Bayer B.M., Daussin S., Hernandez M., et al. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 1990, 29:369-374.
98. Veyries M.L., Sinet M., Desforges B., et al. Effects of morphine on the pathogenesis of murine Friend retrovirus infection. J Pharmacol Exp Ther 1995, 272:498-504.
99. Hu S., Sheng W.S., Lokensgard J.R., et al. Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 2005, 191:886-889.
100. West J.P., Dykstra L.A., Lysle D.T. Immunomodulatory effects of morphine withdrawal in the rat are time dependent and reversible by clonidine. Psychopharmacology (Berl) 1999, 146(3):320-327.
101. Sacerdote P., Gaspani L., Rossoni G., et al. Effect of the opioid remifentanil on cellular immune response in the rat. Int Immunopharmacol 2001, 1(4):713-719.
102. Deng J., Muthu K., Gamelli R., et al. Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. Am J Physiol Cell Physiol 2004, 287(3):C730-C736.
103. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006, 6(4):318-328.
104. Oberbeck R., Schmitz D., Wilsenack K., et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 2004, 11(4):214-223.
105. Stevenson J.R., Westermann J., Liebmann P.M., et al. Prolonged alpha-adrenergic stimulation causes changes in leukocyte distribution and lymphocyte apoptosis in the rat. J Neuroimmunol 2001, 120(1-2):50-57.
106. Spengler R.N., Allen R.M., Remick D.G., et al. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 1990, 145(5):1430-1434.
107. Flierl M.A., Rittirsch D., Nadeau B.A., et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007, 449(7163):721-725.
108. Memiş D., Hekimoĝlu S., Vatan I., et al. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth 2007, 98:550-552.
109. Venn R.M., Bryant A., Hall G.M., et al. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 2001, 86:650-656.
110. Nader N.D., Ignatowski T.A., Kurek C.J., et al. Clonidine suppresses plasma and cerebrospinal fluid concentrations of TNF-alpha during the perioperative period. Anesth Analg 2001, 93:363-369.
111. Weatherby K.E., Zwilling B.S., Lafuse W.P. Resistance of macrophages to Mycobacterium avium is induced by alpha2-adrenergic stimulation. Infect Immun 2003, 71:22-29.
112. Miles B.A., Lafuse W.P., Zwilling B.S. Binding of -adrenergic receptors stimulates the anti-mycobacterial activity of murine peritoneal macrophages. J Neuroimmunol 1996, 71:19-24.
113. Gets J., Monroy F.P. Effects of alpha- and beta-adrenergic agonists on Toxoplasma gondii infection in murine macrophages. J Parasitol 2005, 91(1):193-195.
114. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117(2):289-296.
115. Sud R., Spengler R.N., Nader N.D., et al. Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes/macrophages from pro- to anti-inflammatory. Eur J Pharmacol 2008, 588(2-3):217-231.
116. Kang B.Y., Lee S.W., Kim T.S. Stimulation of interleukin-12 production in mouse macrophages via activation of p38 mitogen-activated protein kinase by alpha2-adrenoceptor agonists. Eur J Pharmacol 2003, 467(1-3):223-231.
117. Yang C.L., Tsai P.S., Huang C.J. Effects of dexmedetomidine on regulating pulmonary inflammation in a rat model of ventilator-induced lung injury. Acta Anaesthesiol Taiwan 2008, 46(4):151-159.
118. Nishina K., Akamatsu H., Mikawa K., et al. The effects of clonidine and dexmedetomidine on human neutrophil functions. Anesth Analg 1999, 88(2):452-458.
119. Bao J.Y., Huang Y., Wang F., et al. Expression of alpha-AR subtypes in T lymphocytes and role of the alpha-ARs in mediating modulation of T cell function. Neuroimmunomodulation 2007, 14(6):344-353.
120. Cook-Mills J.M., Cohen R.L., Perlman R.L., et al. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology 1995, 85(4):544-549.
121. von Dossow V., Baehr N., Moshirzadeh M., et al. Clonidine attenuated early proinflammatory response in T-cell subsets after cardiac surgery. Anesth Analg 2006, 103(4):809-814.
122. Ma D., Hossain M., Rajakumaraswamy N., et al. Dexmedetomidine produces its neuroprotective effect via the α2A-adrenoceptor subtype. Eur J Pharmacol 2004, 502:87-97.
123. Riker R.R., Shehabi Y., Bokesch P.M., et al. SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009, 301:489-499.